Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Spectrum Pharmaceuticals, Inc.    SPPI

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Spectrum Pharmaceuticals, Inc. : Hagens Berman Reminds Spectrum Pharmaceuticals Investors of May 13, 2013, Deadline in Securities Lawsuit

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/03/2013 | 03:35pm CET

Hagens Berman Sobol Shapiro LLP, a national investor-rights law firm, reminds Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) investors of the May 13, 2013, lead plaintiff deadline in a pending lawsuit filed on their behalf. Investors who suffered financial losses can contact Hagens Berman Partner Reed Kathrein, who is leading the firm's investigation, by emailing SPPI@hbsslaw.com.

The lawsuit filed in U.S. District Court identifies a class of Spectrum investors who purchased stock in the company between August 8, 2012, and March 12, 2013, inclusive (the "class period"). Investors who wish to move to be a lead plaintiff in the case may also contact the firm by calling (510) 725-3000 and must move the court no later than May 13, 2013. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.

On March 12, 2013, Spectrum disclosed to investors that it would significantly lower its 2013 revenue guidance on concerns that sales of its drug FUSILEV would be lower than expected. Following the disclosure, Spectrum's stock price fell dramatically, from a close of $12.43 per share on March 12 to a close of $7.79 per share on March 13. The stock has continued to trade at or around $7.00 since the disclosure.

Hagens Berman's investigation centers around whether Spectrum knew and failed to disclose to investors concerns about the sales of FUSILEV.

Hagens Berman reminds whistleblowers with inside information that rewards may be available to individuals who report information leading to a successful enforcement action by the Securities and Exchange Commission. Under the new SEC whistleblower program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC.

More information about this investigation is available at http://www.hb-securities.com/investigations/SPPI.

About Hagens Berman

Hagens Berman Sobol Shapiro LLP is an investor-rights class-action law firm with offices in 10 cities. The Firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the law firm and its successes can be found at www.hbsslaw.com. The Firm's securities law blog is at http://www.meaningfuldisclosure.com.

Firmani + Associates
Mark Firmani, 206-443-9357
Mark@firmani.com


© Business Wire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SPECTRUM PHARMACEUTICALS,
12/02 SPECTRUM PHARMACEUTICALS : Highlights Four Abstracts at the 58th Annual Meeting ..
12/01 Continuing Challenges Hanmi Pharmaceutical Continues to Challenge for New Glo..
11/29 SPECTRUM PHARMACEUTICALS, INC. : Purcell Julie & Lefkowitz LLP Is Investigating ..
11/18 SPECTRUM PHARMACEUTICALS, INC. : 3-DAY DEADLINE: Khang & Khang LLP Announces Sec..
11/18 SPECTRUM PHARMACEUTICALS INC : Other Events (form 8-K)
11/17 SPECTRUM PHARMACEUTICALS, INC. : UPCOMING DEADLINE: Lundin Law PC Announces Secu..
11/17 DEADLINE ALERT : Law Offices of Howard G. Smith Reminds Investors of the Upcomin..
11/17 SPECTRUM PHARMACEUTICALS : Announces Poziotinib Data Presentation at the 17th IA..
11/16 SPECTRUM PHARMACEUTICALS : SPPI) Files An 8-K Results of Operations and Financia..
11/16 SPECTRUM PHARMACEUTICALS, INC. : APPROACHING DEADLINE: Khang & Khang LLP Announc..
More news
Sector news : Biotechnology & Medical Research - NEC
12/03DJJOHNSON & JOHNSON : Boosts Actelion Bid -Bloomberg
12/02 Pharma execs weigh in on possible changes under Trump
11/30 ACTELION : Rejecting J&J could leave Actelion with 'lot of explaining to do'
11/28 Actelion's ambitious independent-minded CEO will drive up takeover price
11/26DJWHAT'S NEWS : Business & Finance -- WSJ
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
11/18 FDA rejects Spectrum Pharma's NDA for QAPZOLA
11/14 Spectrum Pharma Q3 top line up 17%; net loss narrows
11/14 Spectrum Pharmaceuticals beats by $0.23, misses on revenue
11/04 After Hours Gainers / Losers
11/03 Spectrum Pharmaceuticals beats on revenue
Advertisement
Financials ($)
Sales 2016 139 M
EBIT 2016 -66,1 M
Net income 2016 -74,9 M
Debt 2016 -
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017
Capi. / Sales 2016 2,33x
Capi. / Sales 2017 2,82x
Capitalization 322 M
More Financials
Chart SPECTRUM PHARMACEUTICALS,
Duration : Period :
Spectrum Pharmaceuticals,  Technical Analysis Chart | SPPI | US84763A1088 | 4-Traders
Full-screen chart
Technical analysis trends SPECTRUM PHARMACE...
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 9,00 $
Spread / Average Target 125%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Rajesh C. Shrotriya Chairman & Chief Executive Officer
Joseph G. Turgeon President & Chief Operating Officer
Kurt A. Gustafson Chief Financial Officer & Executive Vice President
Stuart Mitchell Krassner Independent Non-Employee Director
Anthony E. Maida Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
SPECTRUM PHARMACEUTICA..-32.01%322
INCYTE CORPORATION-5.68%19 219
QUINTILES IMS HOLDINGS..11.90%18 225
CELLTRION, INC.--.--%9 953
SEATTLE GENETICS, INC.44.41%9 442
LONZA GROUP AG11.34%9 247
More Results